As we approach the end of 2024, Leaderboard Branding proudly stands at the forefront of pharmaceutical branding, showcasing our unparalleled expertise across a diverse range of therapeutic areas. From neurology to oncology, dermatology to endocrinology, we have consistently delivered and supported innovative brands, solidifying our position as industry leaders.

Among our most meaningful and robust endeavors is the development of orphan disease drug brands. This year alone, more than 20% of our FDA approvals were in the rare disease space, underscoring our role as a trusted partner in tackling the unique challenges and opportunities these diseases present. Though individually rare, these diseases collectively impact over 400 million people around the globe, making each drug approval profoundly significant.

Leaderboard excels in providing creative naming solutions, conducting comprehensive patient safety analyses, and offering expert regulatory submission guidance. In 2024, we proudly introduced brands such as Miplyffa, Kebilidi, and Torpenz, offering hope to patients with rare conditions like Niemann-Pick Disease, AADC Deficiency, and Tuberous Sclerosis Complex (TSC). Our other notable brand approvals include Winrevair, Ocrevus Zunovo, and Yorvipath.

Looking ahead to 2025, Leaderboard is eager to forge new partnerships with pharmaceutical companies, both large and small. Together, we will continue to develop groundbreaking brands that transform patient lives, setting new standards in the industry.

To learn more about our naming services, visit our services page here. To speak with one of our naming experts, contact us.